Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

LESSONS LEARNED. A phase I study of the pan‐class I phosphoinositide 3‐kinase inhibitor pilaralisib (in capsule formulation) in advanced solid tumors established the maximum tolerated dose as 600 mg once daily. The current study investigated pilaralisib in tablet formulation. Pilaralisib tablets wer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Edelman, Gerald, Rodon, Jordi, Lager, Joanne, Castell, Christelle, Jiang, Jason, Van Allen, Eliezer M., Wagle, Nikhil, Lindeman, Neal I., Sholl, Lynette M., Shapiro, Geoffrey I.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896717/
https://ncbi.nlm.nih.gov/pubmed/29593099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0691
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados